Clinical Trial Detail

NCT ID NCT04000529
Title Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

gastrointestinal stromal tumor

esophagus squamous cell carcinoma

lung non-small cell carcinoma

head and neck squamous cell carcinoma

Therapies

Spartalizumab + TNO155

Ribociclib + TNO155

Age Groups: senior adult

Additional content available in CKB BOOST